CytomX Therapeutics CTMX Business Segments
| FY'25 | FY'24 | ||
|---|---|---|---|
| Total External Costs by Product | |||
| Cx801Ifnalpha2B | $1.63M-35.0% | $2.51M-78.4% | |
| Other Wholly Owned And Partnered Programs | $1.92M-72.8% | $7.07M+9.0% | |
| Varseta-M | $24.3M+36.2% | $17.85M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does CytomX Therapeutics break its business down?
- CytomX Therapeutics (CTMX) reports total external costs by product across 5 parts — Cx801Ifnalpha2B, Cx904Egfrxcd3, Other Wholly Owned And Partnered Programs, Varseta-M Ep CAM and Varseta-M. Each is extracted from the segment footnotes and tracked over time.
- Where does CytomX Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in CytomX Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
